Clinical Trial Update: A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SM-020 Gel 1.0% assessing safety and efficacy in seborrheic keratoses and non-melanoma skin cancers; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-melanoma Skin Cancer
• Seborrheic Keratosis

Drugs mentioned

• SM-020 Gel 1.0% (SM-020)

Snippet

Sponsor: DermBiont, Inc. | Conditions: Non-Melanoma Skin Cancers | Phase 2 | Status: RECRUITING